all report title image
  • Published On : Mar 2022
  • Code : CMI4957
  • Industry : Pharmaceutical
  • Pages : 186
  • Formats :

Adoptive cell therapy (ACT) is a kind of immunotherapy, in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR). Adoptive cell therapy has made a great difference in treating multiple types of tumors. Some approaches of ACT  involve directly isolating body’s immune cells and simply expanding their numbers, whereas other approaches involve genetically engineering body’s immune cells (via gene therapy) to enhance  cancer-fighting capabilities

The global adoptive cell therapy market is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2022-2030).

Figure 1. Global Adoptive Cell Therapy Market Share (%) in Terms of Value, By Application, 2022

Adoptive Cell Therapy  | Coherent Market Insights

Increasing product approvals is expected to drive the market growth during the forecast period.

The increasing product approvals for adoptive cell therapy is expected to drive the global adoptive cell therapy market growth over the forecast period. For instance, in February 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company, together with IASO Biotherapeutics, a clinical-stage biopharmaceutical company jointly announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) had formally granted Orphan Drug Designation (ODD) to company’s co-developed fully-human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.

CMI table icon

Adoptive Cell Therapy Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$  4,932.5 million
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 21.5% 2030 Value Projection: US$ 23,440.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: CAR-T, TCR-T, NK, TIL
  • By Application: Lymphoma, Leukemia, Others
  • By End User: Hospitals, Cancer Treatment Centers
Companies covered:

Novartis AG,  Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc.,  Transgene SA,  Cellectis,  ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc.,  Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs

Growth Drivers:
  • Increasing research and development for adoptive cell therapy
  • Rising prevalence of  cancer
  • Increasing product approvals
Restraints & Challenges:
  • Side effect associated with adoptive cell therapy

Figure 2. Global Adoptive Cell Therapy Market Share (%), By Type, 2022

Adoptive Cell Therapy  | Coherent Market Insights

Rising  prevalence of cancer is expected to drive the market growth during the forecast period

Rising  prevalence of cancer  is expected to drive the global adoptive cell therapy market growth during the forecast period. For instance, according to the data published by the National Cancer Institute stated that there were an estimated 459,058 people living with leukemia in the U.S. in 2018.

Global Adoptive Cell Therapy Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 426 million infected individuals worldwide, as of February 23, 2022.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global adoptive cell therapy market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening diseases. The coronavirus pandemic has negatively impacted the development, production, and supply of adoptive cell therapy products

Global Adoptive Cell Therapy Market: Restraint

The major factors that is expected to hinder growth of the global adoptive cell therapy market include side effects associated with adoptive cell therapy. Common side effects associated with adoptive cell therapies may include but are not limited to acute kidney injury, bleeding episodes, heart arrhythmias, chills, constipation, cough, cytokine release syndrome (cytokine storm), decreased appetite, delirium, diarrhea, dizziness, and others.

Key Players

Major players operating in the global adoptive cell therapy market include Novartis AG,  Gilead Sciences, Inc.,  Castle Creek Biosciences, Inc.,  Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc.,  Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer.  Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.

Market Dynamics

Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.  Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment  of  multiple  solid  cancers, and Glycostem Therapeutics BV,  a  clinical  stage  and leading Natural Killer (NK) cell manufacturing company announced that they have entered  into  a  development,  license  and supply  agreement.  This  collaboration  between Zelluna Immunotherapy and Glycostem Therapeutics BV will  focus  on  the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK’s) for the treatment of patients with cancer

Key features of the study:

  • This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global adoptive cell therapy market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc.,  Arcellx,  Sana Biotechnology, Inc., Biodesix, Inc,  and Laurus Labs
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market

Detailed Segmentation:

  • Global Adoptive Cell Therapy Market, By Type :
    • CAR-T
    • TCR-T
    • NK
    • TIL
  • Global Adoptive Cell Therapy Market, By Application :
    • Lymphoma
    • Leukemia
    • Others
  • Global Adoptive Cell Therapy Market, By End User :
    • Hospitals
    • Cancer Treatment Centers
  • Global Adoptive Cell Therapy Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novartis AG.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    •  Gilead Sciences, Inc.
    • Castle Creek Biosciences, Inc
    • Lineage Cell Therapeutics, Inc.
    • Transgene SA
    • Cellectis
    • ImmunityBio, Inc
    • Sorrento Therapeutics
    • bluebird bio, Inc.  
    • Arcellx
    • Sana Biotechnology, Inc.
    • Biodesix, Inc
    • Laurus Labs

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global adoptive cell therapy market size is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% between 2022 and 2030
Factors such as increasing research and development for adoptive cell therapy, rising prevalence of cancer, and increasing product approvals are expected to drive the market growth over forecast period.
Lymphoma segment is expected to hold a major market share in the market.
The major factors hampering growth of the market include side effects associated with adoptive cell therapy.
Major players operating in the market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc.,   Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc.,  Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo